Business Wire

VA-VIRTUSTREAM

9.10.2020 13:02:06 CEST | Business Wire | Press release

Share
Virtustream Announces xStreamCare Services™ for Security and Compliance, Enabling Customers to Reduce Risks and Achieve More Proactive Security Posture

Virtustream, an enterprise-class cloud company and Dell Technologies business, announced xStreamCare Services for Security and Compliance today, bringing together advanced security management and monitoring, expert consulting services, and its innovative Trust Platform – a unified, security and compliance management platform.

Virtustream’s latest security solutions provide near real-time visibility into security alerts, intrusion attempts, open vulnerabilities, log analytics, policy management and entitlements across Virtustream’s Enterprise Cloud and Healthcare Cloud platforms, enabling enterprises to achieve a more proactive security posture to protect their business’ IT assets, applications and data.

“Setting the standards of excellence is important to our team at Benjamin Moore. Not only for our products and color offerings, but also for IT security,” said Syed Haider, Director of IT Security, Benjamin Moore. “Virtustream’s deep cloud expertise and focus on understanding our business’ needs make it an excellent fit for us. And by leveraging Virtustream’s new Trust Platform and comprehensive security services – with clear visibility all in one place – we can seamlessly address any issues or risks that may arise.”

For most customers, deploying security services is a manual process, typically managed through multiple platforms. This can be time-consuming, complex and expensive. Without a means to consolidate security data, enterprises struggle to identify their security, compliance and business risks as a whole. In fact, a recent study by Ponemon Institute1 found that 56% of businesses say data breaches occur because of a lack of visibility into the operations of their security programs.

“Our comprehensive approach to security is built on more than a decade of mission-critical cloud experience. With our new security offerings, you can eliminate the need to internally manage the growing number of complexities, cyberattacks and regulatory requirements,” says Pritesh Parekh, Chief Trust & Security Officer at Virtustream. “Our xStreamCare Services for Security and Compliance allow our customers to attain a more robust proactive security posture with unified, near real-time visibility, enabling them to quickly set priorities and make more informed security decisions with precision.”

Unified View Delivers Enhanced Insights and Faster Response Times

Virtustream’s Trust Platform aggregates and automates security data into a unified dashboard. The platform’s simplified and comprehensive view eliminates the need to manually aggregate and process logs from multiple tools and services by providing a clean, near real-time view of an enterprise’s security posture, compliance and risk across multiple workloads.

Virtustream’s Trust Platform is based on the company’s decade of experience securing mission-critical data and applications in the cloud. Further setting the new solution apart from other industry offerings are advanced features, including:

Alerts Dashboard : Displays security alerts with sensitivity levels that originate from Virtustream-deployed security controls with the ability to drill down, filter, and export data.

Vulnerability Dashboard : Prompts proactive protection through awareness of open vulnerabilities as well as their severity and age. Authorized users can define and manage aging and remediation policies.

Log Analytics : Enables ad-hoc queries against aggregated security and OS logs.

Policy Management: Supports customer-defined policies for managing security vulnerabilities.

Compliance Reporting : Allows on-demand download of available reports such as Type 2 SOC 2 + HITRUST with Cloud Security Alliance (CSA) Cloud Controls Matrix and Type 2 Attestation (AT-C 105 and AT-C 205) HIPAA/HITECH.

Asset Management Dashboard : Catalogs all assets in the cloud along with the status of security services.

The Trust Platform is available today on Virtustream Enterprise Cloud and Virtustream Healthcare Cloud.

Security Services for Every Businesses’ IT Needs

The combination of robust security features with actionable visibility helps block attacks proactively before they can penetrate a secure environment. Using security services for cloud-hosted mission-critical applications can also help increase the internal security operation team’s productivity. By off-loading management, internal IT teams can reduce the daily burden of managing security operations. Internal teams can also leverage on-demand access to certified cybersecurity experts and consulting services to address a range of potential internal skills gap.

The Security Essentials Bundle includes anti-virus/anti-malware, host intrusion detection system (IDS), host firewall, host file integrity monitoring, log management and vulnerability scanning. The Security Healthcare Bundle includes all services from the Essentials set as well as data at rest encryption and network intrusion detection. And the Enhanced Bundle includes all of these services along with log forwarding, network firewall policy auditor, data at rest encryption, operating system hardening scans, and SAP virus scanning services.

Find more information on Virtustream Enterprise Cloud , Virtustream Healthcare Cloud , the Trust Center , and on xStreamCare Services for Security and Compliance .

About Virtustream

Virtustream LLC, a Dell Technologies Business, is the enterprise-class cloud company that is trusted by organizations worldwide to migrate and run their mission-critical applications in the cloud. For enterprises, service providers, healthcare organizations and government agencies Virtustream’s xStreamCare Services™ expertise combined with the Virtustream xStream® Management Platform and Infrastructure-as-a Service (IaaS) meets the security, compliance, performance, efficiency and consumption-based billing requirements of complex production applications in the cloud – whether private, public or hybrid.

Virtustream is a trademark of Virtustream LLC. Other trademarks may be trademarks of their respective owners.

1) “The Cybersecurity Illusion: The Emperor Has No Clothes,” by Ponemon Institute, published in July 2019, cited here on Nov. 6, 2019.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye